Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy – A comprehensive cancer center experience
Authors' conclusion
The incidence of new onset and worsening DM in patients treated with ICIs was 1.01%.
Study context
- Population
- Patients who received one or multiple immune checkpoint inhibitors (ICIs) over a 10-year period, comprehensive cancer center
- Participants
- 2,477 patients
- Exposure
- New onset vs Worsening
- New onsetn = 14
- Worseningn = 11
- Outcome
- Incidence of new onset and worsening of DM in patients treated with ICIs
Methodological detailssingle-centre, 10-year period
- Single-centre
- 10-year period
Main finding
As reported in the abstract
Incidence of new onset or worsening DM
New onset
14
events
Worsening
11
events
- Incidence of new onset and worsening diabetes mellitus (DM)
- 1.01%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| DKA at presentationNew onset DM vs Worsening pre-existing DM · all DKA cases in the new onset group | P = 0.02 |
| Personal history of autoimmune disorder or family history of DMNew onset DM vs Worsening pre-existing DM | p greater than 0.05 |
Time to new onset or worsening DM from ICI initiation
- Median time to new onset or worsening DM from ICI initiation
- ∼ 12 weeks
HbA1c · baseline and onset of ICI-induced DM
- Median HbA1c at baseline
- 6.2%
- Median HbA1c at onset of ICI-induced DM
- 8.5%
Personal history of autoimmune disorder or family history of DM
- No significant difference between the two groups
Positive autoantibodies
- Patients with positive autoantibodies
- 3
- Glutamic Acid Decarboxylase (GAD65) antibodies
- 2
- Insulin autoantibodies (IAA)
- 1
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy – A comprehensive cancer center experience. Diabetes Res Clin Pract. Published 11 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →